Thyroid Cancer pp 285-294 | Cite as

Follow-up of Medullary Thyroid Cancer

  • T. Schilling
  • R. Ziegler


A precondition for effective follow-up is knowledge of whether the patient is suffering from the sporadic or the familial form of medullary thyroid cancer (MTC). Mutational analysis of RET proto-oncogene helps to distinguish between these two forms of MTC. In 11.6% of patients with apparent sporadic MTC, a mutation in the RET proto-oncogene is found. This means that these patients have the familial form of MTC, i.e., they suffer from multiple endocrine neoplasia (MEN) type 2 (Table 18.1) [2]. As the clinical presentation may be identical in both forms, every patient with MTC should undergo a mutational analysis of the RET proto-oncogene to distinguish between the sporadic and the familial form (Table 18.2). Patients suffering from MEN 2 have a 50%–100% chance of developing pheochromocytoma and a 10%–20% chance of developing hyperparathyroidism (Table 18.1).


Thyroid Cancer Medullary Thyroid Carcinoma Multiple Endocrine Neoplasia Type Medullary Thyroid Multiple Endocrine Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C (1994) Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 69: 1141–1144PubMedCrossRefGoogle Scholar
  2. 2.
    Berndt I, Reuter M, Saller B, Frank Raue K, Groth P, Grußendorf M, Ritter MM, Höppner W (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:Google Scholar
  3. 3.
    Brierley JD, Tsang RW (1996) External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 25: 141–157PubMedCrossRefGoogle Scholar
  4. 4.
    Buhr HJ, Kallinowski F, Raue F, Frank RK, Herfarth C (1993) Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 72: 3685–3693Google Scholar
  5. 5.
    De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV (1991) Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14: 475–480PubMedGoogle Scholar
  6. 6.
    Di Bartolomeo M, Bajetta E, Bochicchio AM, Carnaghi C, Somma L, Mazzaferro V, Visini M, Gebbia V, Tumolo S, Ballatore P (1995) A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology ( I.T.M.O.) Group. Ann Oncol 6: 77–79Google Scholar
  7. 7.
    Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R (1992) Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2: 113–117PubMedCrossRefGoogle Scholar
  8. 8.
    Frank-Raue K, Raue F, Ziegler R (1995) Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analog octreotide (in German). Med Klin 90: 63–66Google Scholar
  9. 9.
    Gagel RF, Tashjian AH, Cummings T, Pap athanasopoulos N, Kaplan MM, DeLellis RA, Wolfe HJ, Reichlin S (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318: 478–484PubMedCrossRefGoogle Scholar
  10. 10.
    Gimm O, Dralle H (1997) Reoperation in metastasizing medullary thyroid carcinoma: is a tumor stage-oriented approach justified? Surgery 122: 1124–1130PubMedCrossRefGoogle Scholar
  11. 11.
    Giuffrida D, Gharib H (1998) Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 9: 695–701PubMedCrossRefGoogle Scholar
  12. 12.
    Jansson S, Tisell LE, Fjalling M, Lindberg S, Jacobsson L, Zachrisson BF (1988) Early diagnosis of and surgical strategy for adrenal medullary disease in MEN 2 gene carriers. Surgery 103: 11–18PubMedGoogle Scholar
  13. 13.
    Lairmore TC, Ball DW, Baylin SB, Wells SA Jr (1993) Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217: 595–601PubMedCrossRefGoogle Scholar
  14. 14.
    Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, Cassuto D, Bentata PM, Tabarin A, Roger P (1992) Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol (Oxf) 36: 183–186CrossRefGoogle Scholar
  15. 15.
    Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A (1994) Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5: 763–765PubMedGoogle Scholar
  16. 16.
    Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary thyroid carcinoma/multiple endocrine neoplasia type 2. Langenbecks Arch Surg 383: 334–336PubMedCrossRefGoogle Scholar
  17. 17.
    Raue F, Geiger S, Buhr H, Frank-Raue K, Ziegler R (1993) The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma (in German). Dtsch Med Wochenschr 118: 49–52PubMedCrossRefGoogle Scholar
  18. 18.
    Saad MF, Guido JJ, Samaan NA (1983) Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57: 124–128PubMedCrossRefGoogle Scholar
  19. 19.
    Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26: 576–585PubMedGoogle Scholar
  20. 20.
    van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212: 395–400PubMedCrossRefGoogle Scholar
  21. 21.
    Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP (1994) Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73: 432–436PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • T. Schilling
  • R. Ziegler

There are no affiliations available

Personalised recommendations